PD-1 x VEGF/PD-L1 x VEGF 雙特異性抗體：從產業角度進行業務、產品線和競爭分析

Ivonescimab 是一種同類首創且目前同類最佳的PD-1xVEGF 雙特異性抗體，由於其與抗 PD-1 Pembrolizumab（Keytruda）相比具有更優異的臨床特性以及其許可協議的經濟條款，為其管道競爭對手樹立了標竿。與單獨聯合使用抗 PD-（L）1 和抗 VEGF 療法相比，使用單一分子同時抑制 PD-1 和 VEGF（ "協同作用" ）可以改善安全性並增強抗腫瘤活性。具有第三種特異性的下一代三特異性 PD-（L）xVEGF 抗體可能會進一步提高臨床益處。幾乎所有研發的PD-（L）1xVEGF 抗體候選藥物都來自致力於在中國進行開發的中國生物技術公司。這為西方生物製藥公司在全球開發和行銷方面建立策略聯盟提供了機會。

本報告研究了 PD-1 x VEGF/PD-L1 x VEGF 雙特異性抗體市場，並提供了截至2025年 2月的利害關係人、研發管道、臨床概況、潛在候選藥物的分子結構和商業交易的行業見解和分析。

報告中提到的公司

目錄

產品描述

常見縮寫

第1章 執行摘要

第2章 簡介

第3章 PD-（L）1xVEGF 雙特異性/三特異性管分析

• 雙特異性 PD-1xVEGF（R）抗體產品線
• 雙特異性 PD-L1xVEGF 抗體產品線
• 三特異性 PD-L1xVEGF 抗體產品線

第4章 PD-（L）1xVEGF 雙特異性抗體的臨床經驗

• PD-1xVEGF抗體
  • Ivonescimab
  • MHB039A
• PD-L1xVEGF抗體
  • HB0025
  • IMM2510
  • PM8002/BNT327

第5章 PD-（L）1xVEGF（R）雙特異性/三特異性抗體的藥物概況

• PD-1xVEGF（R）雙特異性抗體的藥物概況
  • AI-081
  • CR-001
  • Ivonescimab
  • Jankistomig
  • JS207
  • LM-299
  • MHB0039A
  • NY-500
  • RC148
  • SCTB14
  • SSGJ-707
• PD-L1xVEGF 雙特異性抗體的藥物概況
  • AP505，B1962
  • BB-203
  • HB0025
  • IMM2510，SYN-2510
  • PM8002，BNT327
  • SG1408
• PD-（L1）xVEGF 三特異性抗體的藥物概況
  • CS2009
  • DR30206
  • GB268
  • HC010
  • OGB2350

第6章 競爭與利害關係人分析

• 處於高級開發階段的PD-（L）1xVEGF 抗體利害關係人
• PD-（L）1xVEGF 抗體在早期臨床開發中的利害關係人
• PD-（L）1xVEGF（R）抗體臨床前研究與開發的利害關係人

第7章 PD-（L）1xVEGF 抗體業務公司簡介

• 3SBio
• Akeso Biopharma
• AP Biosciences
• BioNTech
• Biotheus
• Bright Biologics
• Crescent Biopharma
• CStone Pharmaceuticals
• Genor Biopharma
• Hanzhou Sumgen Biotech
• HC Biopharma
• ImmuneOnco Biopharmaceuticals
• Instil Bio
• LaNova Medicines
• Merck & Co
• Minghui Pharmaceutical Co.
• NAYA Biosciences
• OncoC4
• OneGen Biotechnology
• Ottimo Pharma
• RemeGen
• Shanghai Huaota Biopharmaceutical
• Shanghai Junshi Biosciences
• SinoCellTech Group
• Summit Therapeutics
• Tasly Pharmaceutical
• Zhejiang Doer Biopharma

第8章 PD-1/PD-L1 免疫腫瘤抗體市場

• 市場概況
• PD-1抗體市場
• PD-L1抗體市場
• 雙特異性PD-1xCTLA-4/PD-1xLAG-3抗體市場
• 其他尚無商業資訊的PD-（L1）抗體

第9章 商業交易：分拆、融資、許可、合併和收購以及估值

• 衍生產品
• 許可
• 合併和收購
• 估價

第10章 參考資料

This report provides you with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as of February 2025. The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set the bar for competitors in the pipeline for a superior clinical profile compared with anti-PD-1 pembrolizumab (Keytruda) and for economic terms of the licensing agreement. The simultaneous blockade of PD-1 and VEGF ("cooperativity") by one molecule may produce enhanced antitumor activity with an improved safety profile compared with the co-administration of separate anti-PD-(L)1 and anti-VEGF therapies. A next generation of trispecific PD-(L)xVEGF antibodies with a third specificity may even further improve the clinical benefit. Nearly all of the PD-(L)1xVEGF antibody development candidates in the pipeline originate from Chinese biotechnology companies with focus on development in China. This provides an opportunity for Western biopharmaceutical companies for strategic collaborations in global development and marketing.

The report brings you up-to-date with information about and analysis of:

• R&D pipeline of bispecific and trispecific PD-1xVEGF(R) and PD-L1xVEGF antibodies;
• Molecular structure of PD-(L)1xVEGF(R) antibodies in development;
• Preclinical and clinical profile of PD-(L)1xVEGF(R) antibodies;
• Cancer indications in early development and in global development;
• Clinical experience with PD-(L)1xVEGF antibodies;
• Background profile of stakeholders (originator and licensee companies);
• Competitor analysis;
• Established market size for PD-1 and PD-L1 checkpoint inhibitor antibodies;
• Business deals with economic terms: spin-offs, financing, licensing; mergers & acquisitions, company valuation.

In preclinical studies, anti-vascular endothelial growth factor (VEGF) and anti-PD-(L)1 antibodies were found to have synergistic antitumor activity. Anti-VEGF not only inhibits angiogenesis but also increases immune effector cell trafficking and infiltration into the tumor microenvironment, allowing for an immuno-responsive environment, which leads to enhanced efficacy of anti-PD-(L)1 inhibitors. Combining anti-PD-(L)1 antibodies with antiangiogenic agents was found to have antitumor activity and tolerable safety in advanced solid tumors. Clinical studies have shown that the combination of PD-(L)1 and VEGF antibodies significantly improves clinical benefit over PD-(L)1 antibody alone in certain settings.

To combine both targeting approaches, bispecific antibodies targeting PD-1 and VEGF by one molecule have been designed and preclinical studies showed that the combination in one molecule was superior to the combination of two separate molecules in antitumor activity.

As PD-1 and VEGF co-express in the tumor microenvironment, the dual-target design of a bispecific antibody combines PD-1 and VEGF to enable the enrichment and retention of macromolecular drugs in the tumor microenvironment, leading to a reduced distribution in the peripheral blood and a decreased toxicity caused by off-target effects.

Methodology:

This report evaluates the industry landscape of PD-1xVEGF(R) and PD-L1xVEGF bispecific and trispecific antibodies in research and development. The report provides a comprehensive overview of the R&D and partnering activities of pharmaceutical and technology companies in the field of PD-(L)1xVEGF(R) antibodies. This report is based on the identification and description of corporate stakeholders including biopharmaceutical companies and biotechnology companies. All publicly available information is fully referenced, either with scientific references (abstracts, posters, presentations, full paper) or hyperlinks leading to the source of information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

Who will benefit from the report?

• Business development and licensing (BDL) specialists;
• Venture capital, private equity and investment managers;
• Managers of Big Pharma venture capital firms;
• Financial analysts;
• CEO, COO and managing directors;
• Corporate strategy analysts and managers;
• Chief Technology Officer;
• R&D Portfolio, Technology and Strategy Management;
• Clinical and preclinical development specialists.

Companies Mentioned in the Report:

Table of Contents

Product Description

Table of Contents

Frequent Abbreviations

1. Executive Summary

2. Introduction

3. Analysis of PD-(L)1xVEGF bispecific and trispecific pipeline

• 3.1. Pipeline of bispecific PD-1xVEGF(R) antibodies
• 3.2. Pipeline of bispecific PD-L1xVEGF antibodies
• 3.3. Pipeline of trispecific PD-L1xVEGF antibodies

4. Clinical Experience with PD-(L)1xVEGF Bispecific Antibodies

• 4.1. PD-1xVEGF Antibodies
  • 4.1.1. Ivonescimab
  • 4.1.2. MHB039A
• 4.2. PD-L1xVEGF Antibodies
  • 4.2.1. HB0025
  • 4.2.2. IMM2510
  • 4.2.3. PM8002/BNT327

5. PD-(L)1xVEGF(R) Bi- and Trispecific Antibody Drug Profiles

• 5.1. PD-1xVEGF(R) Bispecific Antibody Drug Profiles
  • 5.1.1. AI-081
  • 5.1.2. CR-001
  • 5.1.3. Ivonescimab
  • 5.1.4. Jankistomig
  • 5.1.5. JS207
  • 5.1.6. LM-299
  • 5.1.7. MHB0039A
  • 5.1.8. NY-500
  • 5.1.9. RC148
  • 5.1.10. SCTB14
  • 5.1.11. SSGJ-707
• 5.2. PD-L1xVEGF Bispecific Antibody Drug Profiles
  • 5.2.1. AP505; B1962
  • 5.2.2. BB-203
  • 5.2.3. HB0025
  • 5.2.4. IMM2510; SYN-2510
  • 5.2.5. PM8002; BNT327
  • 5.2.6. SG1408
• 5.3. PD-(L1)xVEGF Trispecific Antibody Drug Profiles
  • 5.3.1. CS2009
  • 5.3.2. DR30206
  • 5.3.3. GB268
  • 5.3.4. HC010
  • 5.3.5. OGB2350

6. Competitor and Stakeholder Analysis

• 6.1. Stakeholders with PD-(L)1xVEGF antibodies in advanced development
• 6.2. Stakeholders with PD-(L)1xVEGF antibodies in early clinical development
• 6.3. Stakeholders with PD-(L)1xVEGF(R) antibodies in non-clinical R&D

7. Profiles of Companies with PD-(L)1xVEGF Antibodies

• 7.1 3SBio
• 7.2. Akeso Biopharma
• 7.3. AP Biosciences
• 7.4. BioNTech
• 7.5. Biotheus
• 7.6. Bright Biologics
• 7.7. Crescent Biopharma
• 7.8. CStone Pharmaceuticals
• 7.9. Genor Biopharma
• 7.10. Hanzhou Sumgen Biotech
• 7.11. HC Biopharma
• 7.12. ImmuneOnco Biopharmaceuticals
• 7.13. Instil Bio
• 7.14. LaNova Medicines
• 7.15. Merck & Co
• 7.16. Minghui Pharmaceutical Co.
• 7.17. NAYA Biosciences
• 7.18. OncoC4
• 7.19. OneGen Biotechnology
• 7.20. Ottimo Pharma
• 7.21. RemeGen
• 7.22. Shanghai Huaota Biopharmaceutical
• 7.23. Shanghai Junshi Biosciences
• 7.24. SinoCellTech Group
• 7.25. Summit Therapeutics
• 7.26. Tasly Pharmaceutical
• 7.27. Zhejiang Doer Biopharma

8. PD-1 and PD-L1 Immuno-Oncology Antibody Markets

• 8.1. Market Overview
• 8.2. PD-1 Antibody Market
• 8.3. PD-L1 Antibody Market
• 8.4. Bispecific PD-1xCTLA-4 and PD-1xLAG-3 Antibody Market
• 8.5. Other PD-(L1) Antibodies without Information on Sales

9. Business Deals: spin-offs, financing, licensing, mergers & acquisitions, valuations

• 9.1. Spin-offs
• 9.2. Licensing
• 9.3. Mergers & Acquisitions
• 9.4. Valuation

10. References

Tables in the Report:

• Table 1: Overview of PD-(L)1xVEGF(R) bi- and trispecific antibodies in the pipeline
• Table 2: Overview bispecific PD-1 x VEGF(R2) antibodies
• Table 3: Overview of structural features of PD-1xVEGF(R) antibodies
• Table 4: Overview bispecific PD-L1 x VEGF antibodies
• Table 5: Overview of structural features of PD-L1xVEGF antibodies
• Table 6: Overview of trispecific PD-(L)1xVEGF antibodies
• Table 7: Overview of structural features of PD-(L)1xVEGF trispecific antibodies
• Table 8: Overview of major efficacy results in clinical phase II studies of ivonescimab
• Table 9: Clinical indications of ivonescimab in phase III studies
• Table 10: Overview of clinical studies with PM8002
• Table 11: Overview of stakeholders with PD-(L)1xVEGF antibodies in advanced development
• Table 12: Overview of Stakeholders with PD-(L)1xVEGF antibodies in early clinical development
• Table 13: Overview of Stakeholders with PD-(L)1xVEGF antibodies in non-clinical R&D
• Table 14: 2023 Total Sales of PD-1 & PD-L1 Antibodies per Class
• Table 15: Sales & Growth Rates of PD-1 & PD-L1 Antibodies 2014-2023
• Table 16: 2023 Individual Sales of Monospecific PD-1 Antibodies
• Table 17: 2023 Individual Sales of Monospecific PD-L1 Antibodies
• Table 18: 2023 Individual Sales of PD-L1 Antibody Combination Regimen
• Table 19: 2023 Individual Sales of Bispecific or Combination PD-1 Antibodies
• Table 20: Approved / Marketed PD-1 & PD-L1 Antibodies without Information on Sales
• Table 21: Overview of business deals related to PD-(L)1 x VEGF(R) targeted bi- and trispecific antibody constructs
• Table 22: Terms of Licensing Deals for PD-(L)1 x VEGF bispecific antibodies